Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Migalastat extension study in Fabry disease
NCT01458119Phase 3Terminated
- Sponsor
- Amicus Therapeutics
- Start
- Oct 2011
- Primary completion
- Feb 2016
- Modality
- Classical Binding Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of migalastat in Fabry disease (FD), sponsored by Amicus Therapeutics. Started Oct 2011; status: terminated.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT01458119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01458119.